U.S. Inhalation Anesthesia Industry

According to a new report by Grand View Research, Inc., the U.S. inhalation anesthesia market is projected to reach a market size of USD 1.06 billion by the year 2030. The market is expected to expand at a compound annual growth rate (CAGR) of 6.1% over the forecast period. This anticipated growth is primarily driven by the increasing demand for shorter hospital stays and a rise in the number of surgical procedures being performed. Inhalation anesthesia is gaining prominence due to its clinical advantages over intravenous anesthesia, offering improved patient outcomes. By delivering anesthetic agents directly through the respiratory tract, it provides a more controlled, efficient, and safe method of sedation, which also proves to be cost-effective in a wide range of clinical settings.

Inhalation anesthesia induces a reversible state of unconsciousness and sensory loss, which is essential for performing surgeries without causing pain or discomfort to patients. It is a preferred method for general anesthesia across various surgical environments, with particular importance in outpatient surgeries, pediatric care, and for patients who are needle-phobic. Additionally, inhalation anesthetics play a significant role in non-surgical diagnostic procedures. These agents are frequently employed outside of the operating room, such as in intensive care unit (ICU) settings for sedation or in managing severe respiratory conditions like status asthmaticus. Furthermore, certain inhalation agents, such as nitrous oxide, are commonly used to provide moderate sedation in dental practices, enhancing patient comfort and procedural ease.

Data from the National Library of Medicine highlights that approximately 40 to 50 million major surgical procedures are performed annually in the United States. This underscores the substantial and growing need for effective anesthesia solutions. Inhalation anesthesia plays a critical role not only in surgical procedures but also in diagnostic interventions such as cancer biopsies, offering necessary sedation and patient comfort during such procedures. According to estimates by the National Cancer Institute, about 2,001,140 new cancer cases are expected to be diagnosed in the U.S. in 2024, including approximately 14,910 cases among children and adolescents. This increasing incidence of cancer is projected to further elevate the demand for inhalation anesthesia, especially within the domains of pediatric and adult oncology, where minimally invasive yet effective sedation is crucial.

Curious about the U.S. Inhalation Anesthesia Market, Download your FREE sample copy now and get a sneak peek into the latest insights and trends.

U.S. Inhalation Anesthesia Market Segments Highlights:

  • Based on drug, the sevoflurane drug dominated the U.S. inhalation anesthesia industry, accounting for the largest revenue share of 75.5% in 2024. The demand is driven by its popularity in day surgery due to the quick attainment of deep anesthesia and faster recovery times.
  • The isoflurane drug segment is expected to grow significantly over the forecast period.
  • Based on application, the maintenance phase dominated the market with the largest revenue share in 2024. However, the induction phase is expected to grow at a significant CAGR over the forecast period.
  • Based on end use, the hospitals segment led the U.S. inhalation anesthesia industry with the largest revenue share in 2024.
  • The Ambulatory Surgical Centers (ASC) end use segment is expected to grow at the fastest CAGR of 7.0% over the forecast period.
  • The growing number of surgical procedures, including orthopedics, ophthalmology, gastroenterology, ENT, cosmetic surgeries, urology, gynecology, and podiatry, in ASCs is expected to drive the demand for inhalation anesthesia in the coming years.

U.S. Inhalation Anesthesia Market Report Segmentation

Grand View Research has segmented the U.S. inhalation anesthesia market based on drug, application, and end use:

U.S. Inhalation Anesthesia Drug Outlook (Revenue, USD Million, 2018 - 2030)

  • Sevoflurane
  • Desflurane
  • Isoflurane
  • Others

U.S. Inhalation Anesthesia Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Induction
  • Maintenance

U.S. Inhalation Anesthesia End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals
  • Ambulatory Surgical Centers (ASC)
  • Others

Key U.S. Inhalation Anesthesia Company Insights

  • Baxter
  • AbbVie Inc.
  • Piramal Enterprises Ltd.
  • Hikma Pharmaceuticals PLC
  • Halocarbon, LLC
  • Sandoz Group AG
  • Fresenius Kabi AG

Order a free sample PDF of the U.S. Inhalation Anesthesia Market Intelligence Study, published by Grand View Research.